Zoledronic Acid + Placebo
ApprovedTerminated 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
Conditions
Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women
Trial Timeline
Mar 1, 2006 → Dec 1, 2013
NCT ID
NCT00333229About Zoledronic Acid + Placebo
Zoledronic Acid + Placebo is a approved stage product being developed by Novartis for Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women. The current trial status is terminated. This product is registered under clinical trial identifier NCT00333229. Target conditions include Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women.
What happened to similar drugs?
20 of 20 similar drugs in Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women were approved
Approved (20) Terminated (5) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01788176 | Phase 2 | UNKNOWN |
| NCT01702415 | Approved | Withdrawn |
| NCT01166178 | Phase 3 | Terminated |
| NCT00844480 | Phase 2 | Terminated |
| NCT01016093 | Phase 2/3 | UNKNOWN |
| NCT00781261 | Phase 2 | UNKNOWN |
| NCT00799266 | Phase 3 | Completed |
| NCT00333229 | Approved | Terminated |
| NCT00320710 | Phase 3 | Completed |
| NCT00375505 | Phase 3 | Completed |
| NCT00145327 | Phase 3 | Completed |
| NCT00132808 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Hormone Receptor Negative Breast Cancer in Premenopausal Women